BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28390927)

  • 1. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.
    Verma MK; Clemens J; Burzenski L; Sampson SB; Brehm MA; Greiner DL; Shultz LD
    J Immunol Methods; 2017 Jul; 446():47-53. PubMed ID: 28390927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
    Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
    Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
    Meyer S; Evers M; Jansen JHM; Buijs J; Broek B; Reitsma SE; Moerer P; Amini M; Kretschmer A; Ten Broeke T; den Hartog MT; Rijke M; Klein C; Valerius T; Boross P; Leusen JHW
    Br J Haematol; 2018 Mar; 180(6):808-820. PubMed ID: 29468712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori).
    Tada M; Tatematsu K; Ishii-Watabe A; Harazono A; Takakura D; Hashii N; Sezutsu H; Kawasaki N
    MAbs; 2015; 7(6):1138-50. PubMed ID: 26261057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
    Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
    Cragg MS; Glennie MJ
    Blood; 2004 Apr; 103(7):2738-43. PubMed ID: 14551143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
    Pievani A; Belussi C; Klein C; Rambaldi A; Golay J; Introna M
    Blood; 2011 Jan; 117(2):510-8. PubMed ID: 21048157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
    Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
    Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.